drugset
Drugs / MRESVIA
last change Jul 2026 re-read 3 minutes ago

MRESVIA

also known as Moderna RSV vaccine

Messenger RNA (mRNA)

Developed for
respiratory syncytial virus infectious disease
Investigated by
Emory University · Open Philanthropy

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) mResvia — 2024-08-22 europa.eu ↗

Trials 1

today
EU approved 2024
NCT07185399 · Ph 4
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT07185399 Oct 2025 → Jul 2026 overdue respiratory syncytial virus infectious disease Emory University Active not recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MRESVIA “Participants will receive the MRESVIA vaccine (Moderna RSV vaccine) as part of the study.” NCT07185399 ↗
Known as Moderna RSV vaccine “Participants will receive the MRESVIA vaccine (Moderna RSV vaccine) as part of the study.” NCT07185399 ↗
Modality Messenger RNA (mRNA) “mRNA-based RSV vaccine” NCT07185399 ↗
Route Intramuscular “intramuscular injection” NCT07185399 ↗